Octreotide in the Prevention of Postoperative Complications After Pancreaticoduodenectomy

• Status: Completed
• Trial end date: 2017-04-01
• Target enrollment: 0
• Participant gender: All

Summary

pancreaticoduodenectomy (PD) is the standard operation for treatment of patients with benign and malignant pancreatic and periampullary diseases. Despite improved surgical technique and postoperative care, the mortality rate after PD is high reaching up to 30%, due to high incidence of postoperative complications . Pancreatic fistula (PF) is the one of the most frequent complications of PD and the major contributor to postoperative morbidity The aim of this study to evaluate the effect of the perioperative octreotide use after PD for prevention of the postoperative pancreatic fistula. The secondary outcomes are overall postoperative complications, mortality and the cost benefit relationship of the use of the perioperative octreotide.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mansoura University
• Treatments: Octreotide

Criteria

Inclusion Criteria:

1. All patients with pancreatic and periampullary tumours anticipated for PD will be eligible to participate in this trial.

2. patients with non dilated pancreatic duct and soft pancreas

Exclusion Criteria:

Exclusion criteria:

1. Age over 70.

2. Patients who underwent total or distal pancreatic resection.

3. Patients with unresectable disease who will undergo any surgical procedure other than PD for pancreatic and periampullary tumours.

4. Patients underwent neoadjuvant chemotherapy or radiotherapy.

5. PD more than 3mm.

6. firm pancreas.

7. PJ